Buenos Aires - Delayed Quote • ARS
Pfizer Inc. (PFE.BA)
As of 4:10 PM GMT-3. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
58,496,000.00
58,496,000.00
100,330,000.00
81,288,000.00
41,651,000.00
Cost of Revenue
24,954,000.00
24,954,000.00
34,344,000.00
30,821,000.00
8,484,000.00
Gross Profit
33,542,000.00
33,542,000.00
65,986,000.00
50,467,000.00
33,167,000.00
Operating Expense
30,183,000.00
30,183,000.00
28,714,000.00
26,763,000.00
24,338,000.00
Operating Income
3,359,000.00
3,359,000.00
37,272,000.00
23,704,000.00
8,829,000.00
Net Non Operating Interest Income Expense
-585,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
Other Income Expense
-1,716,000.00
-1,716,000.00
-1,556,000.00
1,763,000.00
-415,000.00
Pretax Income
1,058,000.00
1,058,000.00
34,729,000.00
24,311,000.00
7,036,000.00
Tax Provision
-1,115,000.00
-1,115,000.00
3,328,000.00
1,852,000.00
370,000.00
Net Income Common Stockholders
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Diluted NI Available to Com Stockholders
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Basic EPS
0.76
0.76
11.18
7.84
3.46
Diluted EPS
0.74
0.74
10.94
7.70
3.42
Basic Average Shares
2,821,500.00
2,821,500.00
2,804,000.00
2,800,500.00
2,777,500.00
Diluted Average Shares
2,821,500.00
2,821,500.00
2,866,500.00
2,854,000.00
2,816,000.00
Total Expenses
55,137,000.00
55,137,000.00
63,058,000.00
57,584,000.00
32,822,000.00
Net Income from Continuing & Discontinued Operation
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Normalized Income
5,997,890.00
5,997,890.00
35,039,856.00
24,999,276.00
8,205,548.32
Interest Income
1,624,000.00
1,624,000.00
251,000.00
36,000.00
73,000.00
Interest Expense
2,209,000.00
2,209,000.00
1,238,000.00
1,291,000.00
1,449,000.00
Net Interest Income
-585,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
EBIT
3,267,000.00
3,267,000.00
35,967,000.00
25,602,000.00
8,485,000.00
EBITDA
8,000,000.00
9,557,000.00
41,031,000.00
30,793,000.00
13,262,000.00
Reconciled Cost of Revenue
24,954,000.00
23,397,000.00
32,889,000.00
29,330,000.00
7,055,000.00
Reconciled Depreciation
4,733,000.00
6,290,000.00
5,064,000.00
5,191,000.00
4,777,000.00
Net Income from Continuing Operation Net Minority Interest
2,134,000.00
2,134,000.00
31,366,000.00
22,413,000.00
6,630,000.00
Total Unusual Items Excluding Goodwill
-4,891,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Total Unusual Items
-4,891,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Normalized EBITDA
12,891,000.00
14,448,000.00
45,095,000.00
33,592,000.00
14,925,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,027,110.00
-1,027,110.00
-390,144.00
-212,724.00
-87,451.68
12/31/2020 - 1/7/2008
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LLY.MX Eli Lilly and Company
12,600.01
+0.96%
BAYN.DU Bayer AG
27.50
+2.44%
BAYRY Bayer Aktiengesellschaft
7.37
+1.43%
OGN Organon & Co.
18.54
+0.65%
BAYN.DE Bayer Aktiengesellschaft
27.40
+1.88%
AMGN Amgen Inc.
271.03
+0.61%
AZN AstraZeneca PLC
75.26
+0.31%
ABBV AbbVie Inc.
159.76
-4.50%
JNJ Johnson & Johnson
146.34
-0.33%
MRK Merck & Co., Inc.
131.17
+0.35%